Personalized Hormone Replacement Therapy Gains Attention Amid Variable Patient Responses

Women undergoing hormone replacement therapy (HRT) for perimenopausal symptoms experience widely varying outcomes, with over 40% discontinuing treatment within a year. Experts attribute this to genetic and metabolic differences that standard “one size fits all” protocols fail to address. A new gene‑diagnostic tool, FemGene®, categorizes women into three Hormone Archetypes—Responsive, Sensitive, and Silent—to predict HRT efficacy and guide tailored dosing and lifestyle support.

Concurrently, telehealth platforms are expanding access to bioidentical (natural) HRT in the United States. Services such as Evernow, Midi Health, Alloy, Winona, and Gennev offer FDA‑approved estradiol and micronized progesterone, often covered by insurance, with options for personalized compounding and integrated nutritional counseling. These online providers aim to deliver individualized care that aligns with patients’ genetic profiles and symptom priorities.